HOLX

HOLOGIC INC

$76.01 +0.00 (+0.00%) At close · Apr 7

Market Cap

$16.97B

223,244,905

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$4.1B +1.7%

FY2025

Net Income

$565.7M -28.3%

FY2025

Gross Margin

51.65% -3.6pp

FY2025

Operating Margin

17.42% -4.5pp

FY2025

Diluted EPS

$2.49 -25%

FY2025

Operating Cash Flow

$1.06B -17.7%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenue	-5.5%	+1.7%	+4.2%	$4.13B	$4.1B	$4.03B	$4.03B	$4.86B	$5.63B	$3.78B	$3.37B	$3.22B	$3.06B	$2.83B	$2.71B	$2.53B	$2.49B	$2B	$1.79B	$1.68B	$1.64B
Cost of Revenue	—	—	+7.8%	—	$1.6B	—	—	—	—	—	—	$886.6M	$881.8M	$756.8M	$755.5M	$731.3M	$818.16M	$616.84M	$521.19M	$487.06M	$470.3M
Gross Profit	-10.9%	-1.0%	+4.0%	$2.12B	$2.12B	$2.23B	$2.07B	$3B	$3.8B	$2.23B	$1.17B	$1.7B	$1.62B	$1.56B	$1.43B	$1.25B	$290.63M	$274.32M	$243.2M	—	—
Gross Margin	—	—	—	—	51.65%	55.28%	51.4%	61.64%	67.39%	58.98%	34.77%	52.73%	52.99%	55.19%	52.96%	49.22%	11.66%	13.7%	13.59%	—	—
Research & Development	-4.3%	+2.2%	+1.5%	$248.4M	$248.2M	$272.8M	$294.3M	$283.4M	$276.3M	$222.5M	$232.2M	$218.7M	$232.8M	$232.1M	$214.9M	$203.2M	$197.65M	$130.96M	$116.7M	$104.31M	$94.33M
Selling & Marketing	-0.5%	+5.1%	+5.5%	$609.4M	$620.6M	$585.4M	$595.2M	$630.3M	$561.2M	$484.6M	$564.9M	$544.6M	$498.6M	$415.1M	$363M	$331.7M	$342.14M	$322.31M	$286.73M	$247.37M	$238.98M
General & Administrative	+3.3%	+4.8%	+5.6%	$461.4M	$449.3M	$409.4M	$392.4M	$407.7M	$433.2M	$356M	$332.3M	$366.1M	$343.3M	$267.3M	$261M	$259.8M	$227.68M	$220.04M	$158.79M	$148.34M	$148.83M
Amortization of Intangibles	-31.7%	-18.4%	-18.4%	$12M	$14.4M	$29.2M	$28.1M	$45.2M	$42.2M	$39.7M	$318.5M	$319.4M	$62.5M	$89.7M	$110.2M	$113.8M	$112.6M	$72.04M	$58.33M	$54.86M	$51.21M
Depreciation & Amortization	-11.3%	-4.4%	-4.8%	$295.4M	$299.8M	$309M	$323.4M	$430.1M	$406.9M	$376M	$463.1M	$480.3M	$449.2M	$465.4M	$491.4M	$523.2M	$516.01M	$345.75M	$304.74M	—	—
Restructuring Charges	+128.4%	+13.3%	0.0%	$28.6M	$28.6M	$41.1M	$12M	$2.4M	$9.3M	$15.3M	$6.6M	$14.2M	$13.3M	$10.5M	$28.5M	$51.7M	$32.81M	$17.52M	-$71K	—	$797K
Total Operating Expenses	+1.1%	+4.6%	+3.7%	$1.4B	$1.4B	$1.35B	$1.4B	$1.36B	$1.32B	$1.12B	$1.29B	$1.93B	$250.8M	$1.01B	$977.6M	$965.8M	—	—	—	—	—
Total Costs & Expenses	+28.3%	—	—	$3.34B	—	—	—	—	—	—	—	—	—	—	—	—	$3.4B	$1.89B	$1.41B	$1.61B	$3.65B
Operating Income	-24.2%	-8.4%	+4.6%	$721.5M	$714.3M	$882.6M	$668.4M	$1.64B	$2.48B	$1.11B	-$123.8M	-$237.9M	$1.37B	$548.6M	$455.1M	$279.7M	-$906.28M	$113.72M	$374.45M	$69.94M	-$2.02B
Operating Margin	—	—	—	—	17.42%	21.9%	16.58%	33.73%	44.04%	29.26%	-3.68%	-7.39%	44.8%	19.37%	16.82%	11.05%	-36.36%	5.68%	20.93%	4.16%	-123.18%
EBITDA	-21.2%	-7.3%	+0.7%	$1.02B	$1.01B	$1.19B	$991.8M	$2.07B	$2.89B	$1.48B	$339.3M	$242.4M	$1.82B	$1.01B	$946.5M	$802.9M	-$390.27M	$459.47M	$679.18M	—	—
Interest Expense	+7.2%	+0.1%	-5.5%	$114.2M	$117.1M	$122.1M	$111.1M	$95.1M	$93.6M	$116.5M	$140.8M	$148.7M	$153.2M	$155.3M	$205.5M	$220.6M	$281.08M	$140.29M	$114.85M	$127.11M	$134.96M
Interest Income	+79.3%	+76.9%	+49.9%	$69.9M	$74.4M	$108.7M	$120.5M	$12.9M	$1.4M	$4.3M	$4.6M	$6.3M	$3.8M	$700K	$1.3M	$1.3M	$1.3M	$2.34M	$1.86M	$1.28M	$1.16M
Other Non-Operating Income	-32.3%	+1.1%	—	-$13.8M	$9.6M	-$4.1M	-$1.7M	$30.9M	-$5.4M	$9.1M	$3.1M	$7.6M	$12.9M	$26.6M	-$11M	-$4.9M	$2.3M	$4.92M	-$4.18M	$901K	-$3.66M
Pretax Income	-24.6%	-7.4%	+14.4%	$663.4M	$681.2M	$865.1M	$676.1M	$1.59B	$2.36B	$1B	-$257.7M	-$418.6M	$1.23B	$415.3M	$177.2M	$48.1M	-$1.19B	-$61.66M	$227.39M	-$54.99M	-$2.15B
Income Tax	-26.1%	—	+9.7%	$119.6M	$115.5M	$75.6M	$220.1M	$286.2M	$491.4M	-$108.6M	-$54.1M	-$307.3M	$475M	$84.5M	$45.6M	$30.8M	-$20.12M	$11.97M	$70.24M	$7.82M	$62.51M
Net Income	-24.3%	-12.7%	+15.7%	—	$565.7M	$789.5M	$456M	$1.3B	$1.87B	$1.12B	-$203.6M	-$111.3M	$755.5M	$330.8M	$131.6M	$17.3M	-$1.17B	-$73.63M	$157.15M	-$62.81M	-$2.22B
Net Margin	—	—	—	—	13.8%	19.59%	11.31%	26.77%	33.23%	29.53%	-6.05%	-3.46%	24.7%	11.68%	4.87%	0.68%	-47.06%	-3.68%	8.78%	-3.74%	-135.4%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	$0	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive Income	-19.9%	-12.2%	+17.5%	$611.7M	$576.4M	$825.6M	$546.6M	$1.12B	$1.86B	$1.1B	-$220.4M	-$120.6M	$771.6M	$313M	$114.5M	-$500K	-$1.16B	-$68.84M	—	—	—
EPS (Basic) USD/shares	-21.6%	-10.0%	+18.2%	—	$2.50	$3.35	$1.85	$5.18	$7.28	$4.24	-$0.76	-$0.40	$2.70	$1.18	$0.47	$0.06	-$4.36	-$0.28	$0.60	-$0.24	-$8.64
EPS (Diluted) USD/shares	-21.4%	-10.0%	+18.7%	—	$2.49	$3.32	$1.83	$5.13	$7.21	$4.21	-$0.76	-$0.40	$2.64	$1.16	$0.45	$0.06	-$4.36	-$0.28	$0.59	-$0.24	-$8.64
Shares Outstanding (Basic Avg) shares	-3.5%	-3.0%	-2.1%	—	226.16M	235.72M	246.77M	251.53M	257.05M	262.73M	269.41M	275.11M	279.81M	280.21M	280.57M	275.5M	268.7M	264.04M	261.1M	258.74M	256.55M
Shares Outstanding (Diluted Avg) shares	-3.6%	-3.0%	-2.4%	—	227.57M	237.55M	248.83M	253.85M	259.71M	264.61M	269.41M	275.11M	285.65M	286.16M	289.54M	278.36M	268.7M	264.04M	264.31M	258.74M	256.55M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $4.59B in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

EV/EBIT

—

P/E (TTM)

31.54×

Medical Instruments & Supplies median 38.86×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	2025-09-27	2024-09-28	2023-09-30	2022-09-24	2021-09-25	2020-09-26	2019-09-28	2018-09-29
Diagnostics	$1,827,200,000	$1,782,000,000	$1,880,100,000	$3,018,500,000	$3,695,000,000	$2,102,100,000	$1,205,500,000	$1,147,400,000
Breast Health	$1,484,100,000	$1,522,900,000	$1,432,700,000	$1,227,800,000	$1,352,300,000	$1,151,900,000	$1,314,200,000	$1,218,200,000
Gyn Surgical	$679,800,000	$641,300,000	$604,200,000	$522,900,000	$488,100,000	$376,100,000	$437,200,000	$422,000,000
Skeletal Health	$109,400,000	$84,100,000	$113,400,000	$93,600,000	$96,900,000	$81,000,000	$94,800,000	$91,200,000
Medical Aesthetics	—	—	—	—	—	$65,300,000	$315,600,000	$339,100,000

By Geography (USD)

Component	2025-09-27	2024-09-28	2023-09-30	2022-09-24	2021-09-25	2020-09-26	2019-09-28	2018-09-29
United States	$3,047,900,000	$3,024,100,000	$3,058,000,000	$3,467,900,000	$3,902,300,000	$2,863,200,000	$2,536,000,000	$2,417,600,000
International	$1,052,600,000	$1,006,200,000	$972,400,000	$1,394,900,000	$1,730,000,000	$913,200,000	$831,300,000	$800,300,000
Europe	$591,000,000	$532,700,000	$520,300,000	$888,500,000	$1,201,800,000	$569,800,000	$396,000,000	$377,500,000
Asia Pacific	$243,300,000	$259,600,000	$255,700,000	$359,700,000	$365,000,000	$226,800,000	$286,000,000	$275,600,000
Other Geographic Regions	$218,300,000	$213,900,000	$196,400,000	$146,700,000	$163,200,000	$116,600,000	$149,300,000	$147,200,000

By Product & Service (USD)

Component	2025-09-27	2024-09-28	2023-09-30	2022-09-24	2021-09-25	2020-09-26	2019-09-28	2018-09-29
Product	$3,256,100,000	$3,255,100,000	$3,279,900,000	$4,191,200,000	$4,967,300,000	$3,227,000,000	$2,771,300,000	$2,643,900,000
Disposables	$2,617,700,000	$2,490,200,000	$2,539,400,000	$3,603,600,000	—	—	—	—
Service	$825,500,000	$758,200,000	$730,500,000	$652,400,000	$598,100,000	$516,600,000	$568,300,000	$551,800,000
Capital Equipment, Components and Software	$638,400,000	$764,900,000	$740,500,000	$587,600,000	$769,100,000	$665,900,000	$984,900,000	$977,200,000
Other Type of Revenue	$18,900,000	$17,000,000	$20,000,000	$19,200,000	$66,900,000	$32,800,000	$27,700,000	$22,200,000
Consumables	—	—	$2,539,400,000	$3,603,600,000	$4,198,200,000	$2,561,100,000	$1,786,400,000	$1,666,700,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	2025-09-27	2024-09-28	2023-09-30	2022-09-24	2021-09-25	2020-09-26	2019-09-28	2018-09-29
Diagnostics	$599,900,000	$509,500,000	$597,800,000	$1,359,400,000	$2,140,100,000	$929,700,000	$163,100,000	$145,500,000
Breast Health	$436,800,000	$476,700,000	$393,500,000	$183,200,000	$284,200,000	$192,800,000	$399,300,000	$399,700,000
Gyn Surgical	$204,600,000	$224,500,000	$203,100,000	$104,900,000	$58,900,000	$42,000,000	$99,200,000	$58,300,000
Skeletal Health	-$3,700,000	-$500,000	$12,800,000	-$7,300,000	-$2,900,000	-$2,400,000	-$4,200,000	$3,300,000
Medical Aesthetics	—	—	—	—	—	-$57,100,000	-$781,200,000	-$844,700,000

Operating Margin by Segment (%)

Component	2025-09-27	2024-09-28	2023-09-30	2022-09-24	2021-09-25	2020-09-26	2019-09-28	2018-09-29
Diagnostics	32.8%	28.6%	31.8%	45%	57.9%	44.2%	13.5%	12.7%
Breast Health	29.4%	31.3%	27.5%	14.9%	21%	16.7%	30.4%	32.8%
Gyn Surgical	30.1%	35%	33.6%	20.1%	12.1%	11.2%	22.7%	13.8%
Skeletal Health	-3.4%	-0.6%	11.3%	-7.8%	-3%	-3%	-4.4%	3.6%
Medical Aesthetics	—	—	—	—	—	-87.4%	-247.5%	-249.1%

Key facts CIK 859737 CUSIP 436440101 13F (30d) 27 filings 6 filers Visit website Investor relations